San Diego-based Sangart has gone missing in action after apparently burning through more than a quarter-billion dollars of Leucadia National cash.
ImmunGene is working to get its lead armed-antibody cancer treatment from the lab to the clinic, and now the California company has $9 million in Series A cash to light the way.
A pair of prominent pharma players are partnering up with a few marquee European VCs to back an up-and-coming immunotherapy biotech based in Vienna.
As biotech venture funding plods along at a middling pace, A-list investor OrbiMed has bagged $735 million for its 5th fund, cash earmarked for life sciences companies across all stages of development.
Biopharma backer NovaQuest has closed a $459 million fund, cash the company will use to push promising, late-stage projects toward commercialization.
Fidelity Biosciences is placing a big bet on gene therapy, funding the launch of startup Dimension Therapeutics with some licensed patents and a plan to develop novel treatments for hemophilia.
A pair of scientifists with deep roots in the Alzheimer's field is partnering up with two high-profile antibody development experts with a well-developed platform technology to launch a new biotech with ambitious plans to build a pipeline of new medications to combat the memory-wasting disease. And they're getting $10 million in seed cash from two marquee venture groups to get everything going.
Over the last few months, Carlos Paya has been filling out his management team at Seattle-based Immune Design. And today the biotech CEO detailed an injection of $32.5 million in venture cash--with the near-term prospect of adding $16.5 million more--to finance the biotech's efforts to nail proof-of-concept data on its two top cancer vaccines.
The lead drug is a glutaminase inhibitor, targeting an enzyme that plays a role in tumor metabolism. The biotech plans to identify patient populations that will most benefit from the drug, sticking with a carefully targeted approach that has dominated the cancer drug field.
Venture luminary Frazier Healthcare just closed an overcommitted $377 million fund, and now the Seattle investor has a biotech veteran onboard to help it make bets in life sciences, recruiting former Calistoga Pharmaceuticals CEO Carol Gallagher to serve as partner.